Efficacy analysis of pirarubicin combined with cytarabine in the treatment of 28 patients with acute myeloid leukemia

娄尔烈, 黄勇, 庞爱明. 以吡喃阿霉索为基础的联合化疗方案治疗急性髓系白血病的疗效及其顶后因素分析 [J]. 肿瘤, 2008(6):532.doi: 10.3781/j.issn.1000-7431.2008.06.019.

张之南, 沈悌. 血液病诊断及疗效标准 [M]. 北京:科学出版社, 2007.106.

王艳玲, 杜志喇, 王英曼. VTCP方案治疗急性淋巴细胞白血病42例分析 [J]. 中国综合临床, 2007(2):120.doi: 10.3760/cma.j.issn.1008-6315.2007.02.014.

Kudo K, Kojima S, Tabuehi K. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etopeside regmen in children with Down syndrome and acute myeloid leukemia:the Japanese Childhood AML Cooperative Study Group [J]. Journal of Clinical Oncology, 2007.5442.

王彦艳, 沈晓梅, 张荣艳. 吡柔比星为主联合化疗方案治疗初治急性髓系白血病疗效观察-一项前瞻、开放、随机、多中心临床研究 [J]. 中华血液学杂志, 2010, (11):748.doi: 10.3760/cma.j.issn.0253-2727.2010.11.008.

Fazlina N, Maha A, Jamal R. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias [J]. Hematology, 2007(1):33.

Plesa C, Chelghoum Y, Plesa A. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia:a single-institution experience [J]. Cancer, 2008(3):572.

季美华, 胡彩华, 陶健. TA和DA方案治疗急性单核细胞白血病的疗效比较 [J]. 白血病·淋巴瘤, 2009(2):108.doi: 10.3760/cma.j.issn.1009-9921.2009.02.016.